Pricing Log in Create free account
Saturday 17 October 2026 Export TAK’s income statement to Excel — free account

Takeda Pharmaceutical Co.

TAK Healthcare Drug Manufacturers Specialty & Generic

Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.

19.67 0.22 +1.13%
Market cap
$61.9B
P/E
29.6×
Fwd P/E
—
Dividend yield
1.57%
F-score
4/9
Altman Z
1.03
Beneish M
−2.65
Dividend safety
25/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 13.09
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — 17 2 —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 61,900.00
Revenue 29,991.30
Net Income 2,884.69
Free Cash Flow 7,420.86
Net Debt 27,798.03
Current Ratio 1.14
Debt/Equity 0.65
P/E ratio 29.60
Fwd P/E —
P/S ratio 2.07
P/B ratio 1.31
Past 5Y EPS Growth —
This Y EPS Growth 1.82%
Next Y EPS Growth 60.25% (at or above 15%: strong)
Next Y revenue growth —
Next 5Y EPS Growth 25.94% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.0×, against a ten-year median of 2.5×; over the ten years it ranged from 1.9× in 2018 to 4.9× in 2019.
P/E against its own 10 years 52.76%
10-year low 10-year high
P/S against its own 10 years 71.40%
10-year low 10-year high
P/B against its own 10 years 61.52%
10-year low 10-year high
EV/Sales against its own 10 years 77.81%
10-year low 10-year high
EV/FCF against its own 10 years 69.04%
10-year low 10-year high

Dividends

Payout Ratio 0.46
Annual Dividend Rate 0.31
Annual Dividend Yield 1.57%
total individual payouts
2026 0.31
0.31
2025 0.66
0.34
0.32
2024 0.62
0.29
0.33
2023 0.63
0.31
0.32
2022 0.66
0.33
0.33
2021 0.80
0.41
0.40
2020 0.85
0.42
0.43
2019 1.25
0.42
0.42
0.41
2018 1.40
0.30
0.41
0.30
0.40
2017 1.46
0.36
0.40
0.31
0.40
2016 1.44
0.32
0.44
0.29
0.39
special payouts not included in total or ratios

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 3,263 2,677 4,204 3,324
Receivables 4,814 4,787 5,784 6,024
Inventory 8,348 8,035 9,218 9,118
Other 1,230 1,142 1,192 1,382
17,654 16,640 20,397 19,847
2024 2025 2026 Q'26
Payables 3,778 3,139 3,243 2,815
ST’ Debt 2,534 3,623 3,380 3,276
Other 8,890 8,900 11,423 10,583
15,960 16,543 18,692 17,417

Compound Annual Growth %

10y 5y 3y
Sales 7.08% (0.21%) (0.07%)
Cash Flow 41.64% (6.27%) (1.68%)
Earnings 0.00% 0.00% 0.00%
Book Value 11.38% 0.15% 1.41%

Revenue $m

Jun Sep Dec Mar Year
’26 7,685 — — — —
’26 7,636 — — — 29,738
’25 7,731 — — — 30,238
’24 7,728 7,197 7,556 6,939 29,420
’23 7,488 7,217 7,786 7,313 29,803
’22 8,641 7,688 7,931 7,504 31,764
’21 7,457 7,416 8,033 7,153 30,059
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 804 — — — —
’26 1,486 2,550 6,285 — 6,873
’25 1,090 1,934 5,511 — 6,977
’24 675 1,335 967 1,966 4,943
’23 649 1,549 2,655 2,378 7,231
’22 1,518 2,122 2,938 3,417 9,996
’21 1,357 2,328 2,171 3,647 9,503
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 161 — — — —
’26 1,013 2,198 4,050 — 4,179
’25 208 1,486 3,618 — 4,472
’24 (1,291) 1,017 477 1,481 1,685
’23 (109) 1,306 2,309 (958) 2,549
’22 1,134 1,729 2,538 2,955 8,356
’21 980 2,306 1,785 2,645 7,717
Fiscal quarters ending in the months shown.

EPS $

Jun Sep Dec Mar Year
’26 0.22 — — — —
’26 0.27 — — — (0.32)
’25 0.19 — — — 0.22
’24 0.21 (0.11) 0.23 (0.02) 0.30
’23 0.26 0.14 0.29 0.08 0.75
’22 0.58 0.13 0.17 (0.23) 0.65
’21 0.25 0.01 0.28 0.59 1.13
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.9
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 20.20 15.50 16.10 12.43 13.17 12.28 13.19 12.58 12.80 14.84

Analyst estimates 2027–2029

Powerpack
High 29.15 31.29 21.61 20.42 19.97 15.66 17.15 15.08 15.78 19.89
People
People Employees 27,230 27,230 49,578 47,495 47,000 47,347 49,095 49,281 47,455 47,000
Revenue/emp, $m 0.59 0.59 0.38 0.64 0.64 0.67 0.61 0.60 0.64 0.63
Income, $m
Income, $m Revenue 16,108 15,935 18,875 30,279 30,059 31,764 29,803 29,420 30,238 29,738
Gross margin, % 67.74 71.99 68.54 66.89 131.09 68.99 69.11 66.54 65.51 65.12
EBT 1,333 1,955 854 (559) 3,443 2,693 2,776 364 1,156 (940)
EBT margin, % 8.28 12.27 4.52 (1.85) 11.45 8.48 9.31 1.24 3.82 (3.16)
Net income 1,074 1,680 981 407 3,536 2,048 2,346 995 714 (1,004)
Depreciation 2,072 1,639 2,452 5,370 5,261 5,190 4,917 5,023 5,025 4,759
Per share, $
Per share, $ Revenue 10.31 10.20 9.82 9.72 9.62 10.16 9.60 9.40 9.58 9.44
Earnings 0.68 1.08 0.51 0.13 1.14 0.66 0.76 0.31 0.22 (0.32)
Cash flow 1.56 2.18 1.54 1.98 3.04 3.20 2.33 1.58 2.21 2.18
Capex (0.65) (0.72) (0.39) (0.61) (0.57) (0.52) (1.51) (1.04) (0.79) (0.86)
Free cash flow 0.91 1.46 1.15 1.37 2.47 2.67 0.82 0.54 1.42 1.33
Book value 11.60 11.63 24.17 13.97 15.58 16.18 15.15 16.04 14.50 15.57
Shares, m 1,562 1,562 1,923 3,114 3,124 3,127 3,104 3,129 3,158 3,150
Valuation, ×
Valuation, × P/E 0.00 65.94 9.76 116.50 16.02 21.80 21.40 42.87 49.75 27.45
P/S 2.38 2.40 1.92 1.56 1.90 1.41 1.72 1.45 1.59 1.94
P/B 2.13 2.02 1.76 1.09 1.17 0.89 1.09 0.85 0.95 1.17
EV/Sales 2.51 2.79 2.29 2.91 3.03 2.38 2.67 2.48 2.55 2.83
EV/FCF 4.21 4.63 5.44 20.62 11.82 9.06 31.18 43.28 11.06 7.77
Cash, $m
Cash, $m Operating cash flow 2,431 3,401 2,956 6,162 9,503 9,996 7,231 4,943 6,977 6,873
Capex (1,014) (1,128) (751) (1,887) (1,786) (1,640) (4,682) (3,258) (2,505) (2,694)
Free cash flow 1,417 2,273 2,206 4,275 7,717 8,356 2,549 1,685 4,472 4,179
Balance, $m
Balance, $m Working capital (980) 3,072 4,858 2,701 8,833 3,986 (621) 1,694 97 1,706
Total debt 10,647 8,871 51,759 46,858 43,572 38,674 32,429 33,422 29,801 32,220
Net debt 7,149 5,494 45,230 40,847 34,146 30,887 28,332 30,159 27,124 28,016
Shareholders’ equity 18,125 18,157 46,472 43,493 48,665 50,583 47,025 50,191 45,777 49,042
Returns, %
Returns, % ROA 2.96 4.34 1.21 0.34 2.95 1.72 2.13 0.96 0.72 (1.02)
ROIC 3.58 5.75 1.26 0.68 17.72 3.15 3.01 1.15 1.94 0.03
ROE 6.14 9.27 3.04 0.90 7.67 4.13 4.81 2.05 1.48 (2.12)
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Takeda Pharmaceutical Co. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TAK Takeda Pharmaceutical Co. $61.9B 29.6× — +1.71% (above 0%: growing) −4.35% (below 0%: shrinking) −95.56% (below 0%: shrinking) 66.66% 16.51%
TEVA Teva Pharmaceutical Industries Ltd. $47.9B 65.9× 30.7× −0.81% (below 0%: shrinking) n/m +121.43% (above 0%: growing) 51.98% (2.03%) Compare
HLN Haleon PLC Sponsored ADR $43.7B 22.6× 17.6× −0.32% (below 0%: shrinking) +40.00% (above 0%: growing) −42.94% (below 0%: shrinking) 62.88% 25.36% Compare
ZTS Zoetis Inc. $32.4B 13.0× 12.3× −0.24% (below 0%: shrinking) +2.48% (above 0%: growing) +17.43% (above 0%: growing) 72.73% 37.56% Compare
UTHR United Therapeutics Corporation $23.2B 17.6× 20.1× −1.92% (below 0%: shrinking) +13.99% (above 0%: growing) +58.76% (above 0%: growing) 87.30% 42.23% Compare
VTRS Viatris Inc. $20.9B — (loss-making) 61.1× +4.88% (above 0%: growing) n/m +101.08% (above 0%: growing) 38.77% 0.17% Compare
NBIX Neurocrine Biosciences, Inc. $13.9B 19.2× 30.5× +39.49% (above 0%: growing) +31.19% (above 0%: growing) +43.69% (above 0%: growing) 97.58% 15.80% Compare
ELAN Elanco Animal Health Incorporated $11.8B — (loss-making) 278× +10.23% (above 0%: growing) +450.00% (above 0%: growing) +35.56% (above 0%: growing) 58.33% 7.97% Compare
RDY Dr. Reddy's Laboratories Ltd $10.7B 32.9× 24.3× −14.44% (below 0%: shrinking) −70.00% (below 0%: shrinking) −143.40% (below 0%: shrinking) 46.54% 4.81% Compare
Median of peers $22.1B 20.9× 27.4× −0.28% +22.59% +39.63% 60.61% 11.89%

All 86 Drug Manufacturers Specialty & Generic stocks →

Takeda Pharmaceutical Co. (TAK) key facts

  • Concern: Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
  • Takeda Pharmaceutical Co. (TAK) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, TAK traded at $19.67, a market capitalization of $61.9 billion.
  • Takeda Pharmaceutical Co. pays an annual dividend of $0.31 per share, a yield of 1.57%, with a payout ratio of 46.5%.
  • Return on equity was −2.12% and debt-to-equity 0.65.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.03 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

Takeda Pharmaceutical Co. (TAK) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/TAK · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com